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Introduction
Bone repair is a complex process involving the participa-
tion of several cell types, signal transduction pathways
and biochemical events [1]. Because it is initiated by a
skeletal injury, which induces an inflammatory response,
chemical mediators of inflammation are also involved in
this process [2]. Prostaglandins, a class of compounds
known to mediate inflammation and shown to have effects
on bone formation and resorption, are essential in bone
repair [3].
Prostaglandin synthesis is initiated with the release of
arachidonic acid from membrane phospholipids. The subse-
quent conversion of arachidonic acid to prostaglandin H2
(PGH2) is catalyzed in two steps by cyclooxygenase [4].
Synthase enzymes then convert PGH2 to specific
prostaglandins such as PGD2, PGE2, PGF2α, prostacyclin
and thromboxane. Thus, cyclooxygenase activity is essential
for normal prostaglandin production and is the rate-limiting
enzyme in the synthetic pathway. The two recognized forms
of this enzyme, cyclooxygenase-1 (COX-1) and cyclooxyge-
nase-2 (COX-2) are encoded by two separate genes [5,6].
COX-1 is constitutively expressed by many tissues and
functions as a so-called ‘housekeeping’ enzyme maintaining
homeostatic levels of prostaglandins for the normal function
of several organs, in particular the stomach [7]. In contrast,
COX-2 is induced by an array of stimuli including inflamma-
tion, injury and mechanical stress [8,9].
The role of COX-2 in bone repair has received recent
attention because drugs that inhibit prostaglandin produc-
tion have been shown to inhibit experimental fracture
healing [10–12]. Non-steroidal anti-inflammatory drugs
(NSAIDs) are among the most commonly prescribed
drugs worldwide and are indicated in the treatment of
several forms of arthritis, menstrual pain and headache.
Their ability to decrease inflammation by inhibiting
cyclooxygenase has improved the quality of many people’s
lives but their use has been limited by gastrointestinal side
effects such as dyspepsia, abdominal pain, and, in some
instances, gastric or duodenal perforation or bleeding. The
development of COX-2 inhibitors (coxibs) was a response
to the need for drugs that inhibit prostaglandin production
without side effects [13]. Because most NSAIDs inhibit
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COX-1 and COX-2 with almost equal potency, it was
hoped that the development of COX-2-selective drugs
would be better tolerated and equally efficacious in man-
aging inflammation. However, whereas the selectivity of
this group of compounds might allow inflammation to be
inhibited with minimal effects on certain homeostatic
mechanisms, their role in bone metabolism and repair
remains unclear.
Review of the evidence
To determine the role of COX-2 in bone repair, investiga-
tors have studied fracture healing in animal models of
COX-2 inhibition or deletion. Although several studies
have been reported at scientific meetings, only two have
been published in the peer-reviewed literature [10,12].
Simon  et al. [10] treated rats with the non-selective
NSAID indomethacin and the two most widely prescribed
coxibs, celecoxib and rofecoxib. They showed that all
three drugs inhibited fracture healing, but the effects were
more profound when coxibs were used. They also demon-
strated impaired fracture healing in mice homozygous for a
null mutation in the COX-2 gene. However, whereas the
doses of indomethacin and celecoxib used in the rats
were roughly equivalent to those used in patients, the
dose of rofecoxib was nearly eight times that used to
manage inflammation and four times that used to manage
acute pain. Moreover, whereas the use of these drugs in
the management of acute pain is typically short term (a
few days to two weeks), their continuous usage in these
experiments was a departure from clinical practice.
Zhang et al. [12] reported the critical role of COX-2 in
mesenchymal cell differentiation during skeletal repair.
Using COX-1-null and COX-2-null mice, they demon-
strated the essential role of COX-2 in both endochondral
and intramembranous ossification. Moreover, the healing
of stabilized tibia fractures in COX-2-null mice was signifi-
cantly delayed compared with that in COX-1-null mice.
The histology of the fractures in the COX-2-null mice
showed a persistence of undifferentiated mesenchyme
and a marked reduction in osteoblastogenesis resulting in
a high rate of nonunions. In addition, to elucidate the
mechanism involved in this reduced bone formation,
osteoblastogenesis was studied in bone marrow stromal
cell cultures obtained from COX-2-null and wild-type mice.
Bone nodule formation was reduced by 50% in the COX-
2-null cultures, but this effect was completely rescued by
the addition of PGE2.
The important question raised by these studies is whether
patients who are undergoing a bone repair process can
safely be treated with inhibitors of COX-2. Bone repair is
an essential aspect of fracture healing but is also the
process required for successful spinal fusion, joint
arthrodesis or osteointegration of an orthopedic or dental
implant. The favorable safety profile of COX-2-specific
inhibitors has led to their use at higher doses, which
renders them effective as post-operative and post-fracture
analgesics. However, whereas the use of these drugs in
the management of arthritic conditions seems appropriate,
their use at higher doses to manage pain induced by
skeletal surgery or a fracture has raised concerns.
On the basis of animal studies, COX-2 inhibitors would
seem to be contraindicated in patients undergoing bone
repair. However, there is a paucity of data from clinical
studies, and those that do exist do not support the results
in animals. Moreover, the few clinical reports that have
addressed the role of NSAIDs or coxibs in patients requir-
ing bone repair have been confounded by other factors
[14] or have collected data in a retrospective fashion
[15–17]. Among these, the most well done was a retro-
spective analysis of 288 cases of spinal fusion performed
at a single center [15]. In this study, ketorolac was admin-
istered as a 15 mg intramuscular loading dose followed by
30 mg every six hours as needed. Ketorolac was given to
167 patients, and no NSAID was given to 121. Nonunion
occurred in 5 of 121 (4%) nontreated controls and 29 of
167 (17%) patients receiving ketorolac (odds ratio 4.9).
There was a dose-dependent relationship between
nonunion rate and ketorolac use. Only one clinical study
with a coxib has been reported, and this too was a retro-
spective investigation. Rueben et al. [17] examined
nonunion rates in 106 patients undergoing posterior
spinal fusion and receiving analgesic doses of rofecoxib.
No effect on nonunion rate was noted.
Conclusions
The evidence supporting an essential role for COX-2 in
experimental bone repair is strong. However, there are no
randomized, controlled trials in patients. In the absence of
these kinds of prospective study, it is tempting to trans-
late animal data to our management of patients. However,
before doing this, certain points must be considered.
Most of the studies in animals have evaluated healing at
fairly early time points. Because most patients heal frac-
tures or fuse spinal segments over a period of several
months, but require drugs to manage their pain for only a
few days or weeks, it is unclear whether short-term inhibi-
tion of COX-2 is really significant to the quality or timeli-
ness of the healing. Indeed, the study by Zhang et al. [12]
showed that restoration of PGE2 levels immediately
rescues the effects of an absence of COX-2. Thus, with-
drawal of the drug in a patient might lead to a restoration
of prostaglandin synthesis and a normal bone repair
process.
Another point relates to the use of indomethacin in the
inhibition of heterotopic ossification in patients who have
sustained a pelvic fracture. These patients are at risk for
developing heterotopic ossification, which could impair
hip function. Indomethacin inhibits heterotopic ossification7
but does so without preventing healing of the pelvic frac-
ture [18]. Although a critical analysis was not performed to
detect a measurable effect on fracture healing in these
patients, no clinically apparent problem was reported.
In the absence of randomized controlled studies, definitive
statements concerning the use of NSAIDs or coxibs in
patients undergoing a bone repair process cannot be
made. However, on the basis of animal data and limited
clinical information, some recommendations can be pro-
posed. For now, although I would not dismiss the use of
these drugs in the management of post-fracture or post-
operative pain in patients requiring bone healing, I would
advise that physicians and their patients be familiar with
the information and make decisions accordingly. I would
advise that if these drugs are used as analgesics in these
settings, their administration be for fairly short periods of
time, probably not to exceed 10–14 days. I would be less
inclined to use these drugs if a patient had a comorbid
condition that might prevent or delay bone repair, such as
smoking, glucocorticoid use, metabolic bone disease, or
diabetes. In patients who use standard anti-inflammatory
doses of NSAIDs or coxibs, and who undergo joint
replacement surgery with a prosthesis that requires bone
ingrowth, I would recommend that these drugs be discon-
tinued until osteointegration has occurred (approximately
three to six months).
The ability to resolve the role of COX-2 inhibitors in bone
repair with a randomized, controlled trial would be chal-
lenging. The recruitment of sufficient numbers of patients
to achieve statistical power, the development of reliable
methods to measure the bone repair endpoint, and the
randomization of patients to treatment groups in an ethical
experimental design require substantial thought and plan-
ning. Until such data are available, the role of COX-2 in
human bone repair must be inferred from basic science
reports.
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